Investments
237Portfolio Exits
105Funds
12Partners & Customers
1About Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that invests in the invests in biotechnology and life sciences sectors in public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The company was founded in 1999 and is based in New York, New York.
Latest Perceptive Advisors News
Nov 9, 2023
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and its subsidiaries have entered into a new, five-year credit agreement with Perceptive Credit Holdings IV, LP (“Perceptive”), an affiliate of Perceptive Advisors. The Perceptive Credit Agreement provides for a facility of up to $45 million in senior secured term
Perceptive Advisors Investments
237 Investments
Perceptive Advisors has made 237 investments. Their latest investment was in Viridian Therapeutics as part of their PIPE on October 10, 2023.
Perceptive Advisors Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
10/30/2023 | PIPE | Viridian Therapeutics | $185M | Yes | 2 | |
9/27/2023 | Series C | Avalyn | $175M | Yes | Catalio Capital Management, Eventide Asset Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Piper Heartland Healthcare Capital, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, SR One, Surveyor Capital, Vida Ventures, and Wellington Management Company | 2 |
8/30/2023 | Series D | Beta Bionics | $100M | No | 5 | |
8/23/2023 | Series B | |||||
7/26/2023 | Series A - II |
Date | 10/30/2023 | 9/27/2023 | 8/30/2023 | 8/23/2023 | 7/26/2023 |
|---|---|---|---|---|---|
Round | PIPE | Series C | Series D | Series B | Series A - II |
Company | Viridian Therapeutics | Avalyn | Beta Bionics | ||
Amount | $185M | $175M | $100M | ||
New? | Yes | Yes | No | ||
Co-Investors | Catalio Capital Management, Eventide Asset Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Piper Heartland Healthcare Capital, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, SR One, Surveyor Capital, Vida Ventures, and Wellington Management Company | ||||
Sources | 2 | 2 | 5 |
Perceptive Advisors Portfolio Exits
105 Portfolio Exits
Perceptive Advisors has 105 portfolio exits. Their latest portfolio exit was Forge Biologics on November 13, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/13/2023 | Acquired | 4 | |||
9/15/2023 | IPO | Public | 3 | ||
5/17/2023 | Acquired | 1 | |||
Date | 11/13/2023 | 9/15/2023 | 5/17/2023 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 3 | 1 |
Perceptive Advisors Fund History
12 Fund Histories
Perceptive Advisors has 12 funds, including Perceptive Xontogeny Venture Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
5/12/2021 | Perceptive Xontogeny Venture Fund II | $515M | 1 | ||
11/16/2020 | Perceptive Credit Opportunities Fund III | $1,100M | 5 | ||
9/1/2020 | Perceptive Credit Opportunities III SLP | $89.85M | 2 | ||
9/1/2020 | Perceptive Credit Opportunities Offshore Fund III | ||||
12/10/2019 | Perceptive Xontogeny Venture Fund |
Closing Date | 5/12/2021 | 11/16/2020 | 9/1/2020 | 9/1/2020 | 12/10/2019 |
|---|---|---|---|---|---|
Fund | Perceptive Xontogeny Venture Fund II | Perceptive Credit Opportunities Fund III | Perceptive Credit Opportunities III SLP | Perceptive Credit Opportunities Offshore Fund III | Perceptive Xontogeny Venture Fund |
Fund Type | |||||
Status | |||||
Amount | $515M | $1,100M | $89.85M | ||
Sources | 1 | 5 | 2 |
Perceptive Advisors Partners & Customers
1 Partners and customers
Perceptive Advisors has 1 strategic partners and customers. Perceptive Advisors recently partnered with LianBio on August 8, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
8/11/2020 | Partner | China | SHANGHAI & PRINCETON , N.J. -- -- LianBio , founded , seeded and incubated by Perceptive Advisors , announced its launch today with a diverse array of potentially transformative therapeutics from MyoKardia , BridgeBio Pharma , Inc. affiliate companies Navire Pharma and QED Therapeutics , as well as a strategic relationship with BridgeBio Pharma , Inc. that provides LianBio preferential access to their portfolio of over 20 product candidates . | 2 |
Date | 8/11/2020 |
|---|---|
Type | Partner |
Business Partner | |
Country | China |
News Snippet | SHANGHAI & PRINCETON , N.J. -- -- LianBio , founded , seeded and incubated by Perceptive Advisors , announced its launch today with a diverse array of potentially transformative therapeutics from MyoKardia , BridgeBio Pharma , Inc. affiliate companies Navire Pharma and QED Therapeutics , as well as a strategic relationship with BridgeBio Pharma , Inc. that provides LianBio preferential access to their portfolio of over 20 product candidates . |
Sources | 2 |
Perceptive Advisors Team
7 Team Members
Perceptive Advisors has 7 team members, including current Founder, Chief Executive Officer, Joseph Edelman.
Name | Work History | Title | Status |
|---|---|---|---|
Joseph Edelman | Aries Capital Partners, and Prudential | Founder, Chief Executive Officer | Current |
Name | Joseph Edelman | ||||
|---|---|---|---|---|---|
Work History | Aries Capital Partners, and Prudential | ||||
Title | Founder, Chief Executive Officer | ||||
Status | Current |
Compare Perceptive Advisors to Competitors
Katan Associates International (KAI) is a merchant bank and strategic consulting firm. The company identifies and analyzes strategic opportunities, transactional requirements, and operational needs and provides an industry perspective essential to creating long-term shareholder value. It provides its services to the pharmaceuticals, biotechnology, and life sciences sectors. It was founded in 2001 and is based in Manhattan Beach, California.
Syncona Partners (LON: SYNC) is an investment company. The company offers services that include founding, building, and funding companies. It makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. The company was founded in 2012 and is based in London, U.K.
StemPoint Capital is an equity asset management firm dedicated to the global life sciences industry. It offers seeks to leverage growth aspects of the biotechnology sector and the defensive qualities of the pharmaceutical industry to potentially generate absolute returns in varying market cycles. StemPoint Capital was founded in 2023 and is based in New York, New York.
Pharma’s Almanac operates as a pharmaceutical company. It offers an in-depth analysis of pharma’s most intensive markets, active business sectors, and major players. The company was founded in 2015 and is based in New York, New York.
Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.
Pagan Research is an online B2B database and business intelligence website. It delivers quality data for the US, Asia, and EU regions' startups, recent fundings, exits, and more. The company was founded in 2016 and is based in Boston, Massachusetts.
Loading...